CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) and Coherus Oncology (NASDAQ:CHRS – Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, dividends, analyst recommendations, institutional ownership, valuation and profitability.
Analyst Ratings
This is a breakdown of current ratings and price targets for CRISPR Therapeutics and Coherus Oncology, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| CRISPR Therapeutics | 1 | 6 | 8 | 2 | 2.65 |
| Coherus Oncology | 1 | 0 | 3 | 0 | 2.50 |
CRISPR Therapeutics currently has a consensus target price of $72.93, indicating a potential upside of 67.26%. Coherus Oncology has a consensus target price of $11.00, indicating a potential upside of 1,922.06%. Given Coherus Oncology’s higher possible upside, analysts clearly believe Coherus Oncology is more favorable than CRISPR Therapeutics.
Volatility & Risk
CRISPR Therapeutics has a beta of 1.92, meaning that its stock price is 92% more volatile than the S&P 500. Comparatively, Coherus Oncology has a beta of 1.03, meaning that its stock price is 3% more volatile than the S&P 500.
Earnings & Valuation
This table compares CRISPR Therapeutics and Coherus Oncology”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| CRISPR Therapeutics | $3.51 million | 1,204.98 | -$581.60 million | ($4.74) | -9.20 |
| Coherus Oncology | $42.17 million | 1.99 | $168.02 million | ($1.03) | -0.53 |
Coherus Oncology has higher revenue and earnings than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Coherus Oncology, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares CRISPR Therapeutics and Coherus Oncology’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| CRISPR Therapeutics | -1,812.07% | -25.59% | -17.89% |
| Coherus Oncology | -253.43% | -274.46% | -69.87% |
Institutional & Insider Ownership
69.2% of CRISPR Therapeutics shares are owned by institutional investors. Comparatively, 72.8% of Coherus Oncology shares are owned by institutional investors. 5.2% of CRISPR Therapeutics shares are owned by company insiders. Comparatively, 7.2% of Coherus Oncology shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Summary
Coherus Oncology beats CRISPR Therapeutics on 8 of the 15 factors compared between the two stocks.
About CRISPR Therapeutics
CRISPR Therapeutics AG is a biotechnology company focused on developing gene-based medicines using CRISPR/Cas9, a gene-editing technology that can make targeted changes to DNA. Founded in 2013, the company is headquartered in Zug, Switzerland, and maintains U.S. operations in Cambridge, Massachusetts. Its lead product, Casgevy (exa-cel), was developed with Vertex Pharmaceuticals for people with sickle cell disease and transfusion-dependent beta thalassemia. It was the first therapy based on CRISPR gene editing to receive regulatory approval.
About Coherus Oncology
Coherus Oncology, formerly known as Coherus BioSciences, is a commercial-stage biopharmaceutical company focused primarily on developing and commercializing medicines for cancer and other serious diseases. The company has built its business around biologic therapies, including biosimilars and innovative treatments intended to improve access to important medicines. Its portfolio includes UDENYCA (pegfilgrastim-cbq), a long-acting treatment used to reduce the risk of infection associated with chemotherapy, and LOQTORZI (toripalimab-tpzi), an immuno-oncology therapy approved in the United States for certain patients with nasopharyngeal carcinoma.
Receive News & Ratings for CRISPR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRISPR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
